26F2 Aplin, Andrew E. - Thomas Jefferson University - Thomas Jefferson University

Andrew E. Aplin, PhD

Contact Dr. Aplin

Kimmel Cancer Center
233 S. Tenth Street, Suite 522
Philadelphia, PA 19107

(215) 503-7296
(215) 923-9248 fax

Most Recent Peer-reviewed Publications

  1. Targeting mutant NRAS signaling pathways in melanoma
  2. Of Mice and melanoma: PDX system for modeling personalized medicine
  3. Welcome to the New Year!
  4. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization
  5. The state of melanoma: Challenges and opportunities
  6. Fibroblast-derived neuregulin 1 promotes Compensatory ErbB3 receptor signaling in mutant BRAF melanoma
  7. PAX3 and FOXD3 promote CXCR4 expression in melanoma
  8. ErbB3-ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas
  9. Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma
  10. The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox
  11. Game of isoforms: PI3K β-sparing inhibitor is coming
  12. Animal experimentation - questioned again!
  13. The value of thesis advisers
  14. The value of thesis advisers
  15. NF-κB regulation of c-FLIP promotes TNFα-mediated RAF inhibitor resistance in melanoma
  16. What shall we do this year?
  17. RAC1 P29S regulates PD-L1 expression in melanoma
  18. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer
  19. Sestrin2 protein positively regulates AKT enzyme signaling and survival in human squamous cell carcinoma and melanoma cells
  20. Adaptive resistance to RAF inhibitors in melanoma